Every Piece of Elon's Empire Just Started Connecting
Overall Thesis
Elon Musk's previously disconnected ventures (Tesla, SpaceX, AI) are converging into an integrated compute and AI infrastructure business with emerging demand from pharmaceutical companies developing AI-driven cancer treatments.
Narratives
The speakers argue that Tesla's fleet of AI4-chip-equipped vehicles represents an untapped distributed compute resource that can be monetized via Grokbot agent subscriptions, adding a new high-margin revenue stream on top of car sales. They frame this as part of a broader vertical integration of Tesla, SpaceX, and xAI compute, chips, energy, and software that they believe will drive massive future value creation.
Key Arguments
- Millions of idle AI4 chips in parked Teslas could each run multiple Grokbot agent sessions, generating shared revenue split between Tesla, the car owner, and SpaceX/xAI.
- The combined car fleet compute is estimated at roughly a gigawatt, comparable to a major data center, giving Tesla a 'free' distributed compute asset.
- Vertical integration across energy (megapacks), compute (AI4/AI5 chips), robotics (Optimus), software (Grok/Cursor), and connectivity (Starlink) positions Tesla/SpaceX to capture value across every layer of the AI buildout.
- Emerging AI-for-medicine demand (compute-intensive cancer diagnostics/treatment) is cited as a new large compute customer category that could sustain gigawatt-scale compute pricing.
The hosts discuss Moderna's phase three melanoma trial results using mRNA and AI-driven personalized cancer treatment, noting the stock 'more than doubled, nearly tripled' on the news. They speculate the underlying mRNA/AI approach could extend to other cancers and diseases, framing it as an early example of AI transforming medicine and compute demand, but do not make a forward-looking price prediction on Moderna itself.
Key Arguments
- Moderna's five-year trial applying AI to select personalized cancer antigen cocktails reduced cancer recurrence, described as a 'cancer vaccine' style treatment for melanoma.
- Doctors reportedly see potential for the same mRNA/AI approach to apply to breast, pancreatic, and other cancers as well as non-cancer diseases.
- The speakers use Moderna's stock reaction as proof that AI-driven medical breakthroughs can create outsized market value, supporting their broader compute-demand thesis for Tesla/SpaceX.
Hedges & Caveats
- Discussion is speculative about future demand for compute services
- Pharmaceutical applications are still in trial phases
- Revenue projections ($50B per gigawatt per year) are forward-looking estimates
- Dependent on successful scaling of data center buildout